%0 Journal Article %J Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii %@ 1642-395X %V 38 %N 5 %D 2021 %F Aruanno2021 %T Efficacy of omalizumab in reducing latex allergy %X Omalizumab, a humanized monoclonal antibody that binds the CH3 domain near the binding site for the high affinity type-I IgE Fc receptors of human IgE, can neutralize free IgE and inhibit the IgE allergic pathway [1]. The current indications for treatment with omalizumab are limited to severe persistent allergic asthma and chronic spontaneous urticaria (CSU) when it is not controlled by conventional anti-H1 treatment at the maximum dosage. In recent years, several studies [1] have shown that omalizumab is effective in a large number of IgE-mediated and non-IgE-mediated disorders, indicating that omalizumab treatment acts on many levels and not only on immunoglobulins E [2]. %A Aruanno, Arianna %A Chini, Raffaella %A Nucera, Eleonora %P 921-923 %9 journal article %R 10.5114/ada.2021.110072 %U http://dx.doi.org/10.5114/ada.2021.110072